Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials for ...
Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS
Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...
Surrey Alzheimer's drug trial patient shares his experience of donanemab
Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...
Hosted on MSN22h
Worried about dementia – here’s how to get seen at a memory clinic
A timely diagnosis may become even more pressing if new treatments – such as donanemab and lecanemab, which aim to slow the progression ... Only around two per cent get a PET brain scan or lumbar ...
News Medical21h
Alzheimer's & Dementia
Alzheimer’s Disease (AD) is the most common form of dementia worldwide (60-70% of all dementia cases) and is a progressive neurodegenerative disorder.
Exam English20h
B1 Preliminary (PET) Listening
The Listening section is worth 25% of the total score for the exam. Each of the 25 listening questions scores 1 mark.